Key Concept

Key Evidence: A study of the economic burden of cholera in Africa found that 110,837 cases of cholera reported in 2007 resulted in an economic loss of $43.3 million, $60 million and $72.7 million US dollars, assuming life expectancies of 40, 53 and 73 years respectively.

Kirigia, J.M., Gambo, L.G., Yolouide, A., et al 2009. Economic burden of cholera in the WHO African Region. BMC International Health and Human Rights. 9(8).
View Publication >

Key Evidence: Researchers modeled the costs, using the UK’s 2004 economy, of potential pandemic flu in the UK. Costs of illness alone ranged between 0.5% and 1.0% of gross domestic product (£8.4bn to £16.8bn) for low fatality scenarios, 3.3% and 4.3% (£55.5bn to £72.3bn) for high fatality scenarios, and larger still for an extreme pandemic. Vaccination with a pre-pandemic vaccine could save 0.13% to 2.3% of gross domestic product (£2.2bn to £38.6bn); a single dose of a matched vaccine could save 0.3% to 4.3% (£5.0bn to £72.3bn), and two doses of a matched vaccine could limit the overall economic impact to about 1% of gross domestic product for all disease scenarios.

Smith, R.D., Keogh-Brown, M.R., Barnett, T., et al 2009. The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modeling experiment. BMJ. 339.
View Publication >